Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Cartesi (CTSI) amplitude reaches 145.7% within 24 hours, trading volume surges over 3400%, driving price pump followed by a pullback

Cartesi (CTSI) amplitude reaches 145.7% within 24 hours, trading volume surges over 3400%, driving price pump followed by a pullback

Bitget PulseBitget Pulse2026/04/03 03:15
Show original
By:Bitget Pulse

Volatility Overview

CTSI experienced extreme price fluctuations in the past 24 hours, surging from a low of $0.0219 to a high of $0.0538. The current price is $0.036, with an amplitude of 145.7%. Trading volume soared to approximately $162 million, an increase of over 3,400% compared to the previous day, indicating a significant rise in market activity.

Analysis of the Causes for Unusual Movements

- Unusually Large Trading Volume: 24-hour trading volume reached $162 million, up 3,425.6%, mainly concentrated on major exchanges such as Binance ($26.9 million) and Coinbase ($9.7 million), reflecting a sharp rise in market participation.

- Technical Price Breakout: The price rapidly rebounded from the $0.02188 low, breaking through the 20-day moving average and key resistance levels, accompanied by buying support. However, there were no official announcements or significant on-chain transfer events recorded.

Market Views and Outlook

Overall community sentiment is bullish, with 90% bullish votes on CoinMarketCap. Trader opinions are divided; some believe strong demand after the pump could drive further gains (targeting $0.027-0.029), while others warn of upper wick rejections and an overbought RSI, with expectations of a short-term pullback to the $0.022-0.025 support zone.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring, and is provided for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Wall Street Stands Guard as Bessent Strikes Again: Aftereffects of August's "Treasury Turnaround" Persist, November Refinancing Notice Could Be the Next Flashpoint

As the US Treasury prepares to update its debt management plan in November, key clues may emerge on Friday.

智通财经•2026/10/16 01:06

"Coca-Cola belief" never goes out of style! KFC in America says goodbye to Pepsi and embraces Coca-Cola (KO.US); Buffett-style "boring investment" returns to the spotlight

KFC has chosen Coca-Cola as its soda supplier in the United States, abandoning its long-term partner Pepsi. As of the close of the U.S. stock market on Thursday, Coca-Cola's (KO.US) stock price reached a record high, defying the ongoing declines in global tech stocks, especially in the semiconductor and broad AI computing sectors.

智通财经•2026/10/16 01:06

AI financing concerns weigh heavily on chip stocks, global tech sector has lost over $1 trillion this week

Multiple pressures, including rising expectations of a Federal Reserve rate hike and increasing AI financing costs, have led to a massive sell-off in global tech stocks this week. The combined market value of the world's top 20 AI and semiconductor stocks has evaporated by more than $1 trillion, and the semiconductor ETF (SOXX) has recorded its longest losing streak in 11 years. On Thursday, SK Hynix continued to plunge by over 10% in a single day, while Nvidia, Samsung, and SoftBank were not spared.

华尔街见闻•2026/10/16 00:51

Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs

Amid concerns over AI capital expenditures, funds are seeking a "certainty premium." State Street Healthcare ETF reached a record high. Eli Lilly and AbbVie are both approaching their historical highest closing prices, while Gilead and Amgen have surged 7.7% and 7.2% respectively over the past five days. Eli Lilly continues to bet on the future through its GLP-1 dominance and 40 M&A deals totaling $20 billion. AbbVie's core drug Skyrizi has shown positive data for its new subcutaneous formulation, which is expected to extend its patent and drive additional sales.

华尔街见闻•2026/10/16 00:37
Safe Haven Amid AI Crash! Major Pharmaceutical Stocks Approach Historic Highs